IMAB362 + Zoledronic acid + Interleukin-2 (1 million IU) + Interleukin-2 (3 million IU)
Phase 1CompletedDevelopment Stage
CLDN18.2-positive Gastric Adenocarcinoma
CLDN18.2-positive Gastric Adenocarcinoma, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus
Oct 16, 2012 → Oct 13, 2014
About IMAB362 + Zoledronic acid + Interleukin-2 (1 million IU) + Interleukin-2 (3 million IU)
IMAB362 + Zoledronic acid + Interleukin-2 (1 million IU) + Interleukin-2 (3 million IU) is a phase 1 stage product being developed by Astellas Pharma for CLDN18.2-positive Gastric Adenocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01671774. Target conditions include CLDN18.2-positive Gastric Adenocarcinoma, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01671774 | Phase 1 | Completed |
Competing Products
1 competing product in CLDN18.2-positive Gastric Adenocarcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| epirubicin + oxaliplatin + capecitabine + zolbetuximab | Astellas Pharma | Phase 2 | 35 |